October 23, 2012
OxySure (OXYS) May have Developed the Next AED
Imagine that you’re at a sporting event and someone collapses next to you from a sudden heart attack. If you’re like most Americans, you’ll immediately look for an automated external defibrillator (AED) to jumpstart the person’s heart and save a life.
With more than two million units sold so far in the US alone by companies such as Medtronic Inc. (NYSE: MDT), these devices have become commonplace in just about any U.S. facility and represent an industry expected to exceed $2.2 billion by 2017.
The market for AEDs has been driven in part by increased legislation and in part by higher instances of sudden cardiac arrest – due to an aging and society and other health conditions, such as for example obesity. When a cardiac arrest occurs there is a golden window of opportunity – just a few minutes after, during which the need for an immediate electric shock to the heart is paramount, without waiting for emergency responders to arrive at the scene.
But, what about emergency oxygen?
A study by USA Today found that the gap between the onset of an emergency and the arrival of first responders could be between six and 15 minutes. But unfortunately, just five minutes without emergency oxygen can cause permanent damage to the brain and vital organs.
Until now, there has been no way to easily, quickly and safely deliver emergency oxygen by a lay person.
OxySure Systems Inc. (OTCBB: OXYS) has developed a revolutionary new product that’s similar to an AED in that it’s easily administered and requires no training to operate. But instead of shocking the heart, the device provides instant medical-grade oxygen to patients. This is crucial, because after the heart is restarted by the AED, medical oxygen is the next critical need.
Medical grade oxygen is necessary in far more medical emergencies than a sudden cardiac arrest, too. From a common and relatively minor asthma attack at a high school football game to major trauma from a car accident, medical oxygen is vital in these situations to prevent cardiac arrhythmias, tissue injury, damage to vital organs and ultimately an untimely death.
OxySure’s Model 615 generates medical trade oxygen on demand without compressed tanks by combining two dry, inert and non-hazardous powders that can be safely stored. Like an AED, the unit is also very easy to operate by a layperson during times of emergency.
The technology could have enormous potential.
Given the dire need for medical oxygen and the rapid growth of the AED market, OxySure’s technology could have enormous potential around the world, particular as medical oxygen is used in far more emergency situations than defibrillators.
Currently, the company generates the majority of its revenues by selling into the K-12 educational market, where its product has already helped save hundreds of lives. But it has just begun to scratch the potential market for its innovative technology.
To expand into other markets where AEDs are common, OxySure has focused on signing up existing AED distributors to add its product to their line-up. For instance, an agreement was recently inked with AED Professionals to expand into these markets most effectively. And earlier this year, the firm announced a similar agreement with Grainger and another with Systemax’s Global Industrial to distribute its products around the world.
The company hopes that these products will continue to gain traction in the market over the coming quarters. If OxySure can be successful in garnering just 5% of the AED marketplace, the firm could see sustained revenues in excess of $110 million per year.
This means significant potential for investors.
OxySure trades with a market capitalization of around $15 million, which could represent just a fraction of its potential valuation if the company is able to execute on all of their plans. The Company has already demonstrated its ability to achieve many critical milestones, such as FDA approval, ANVISA approval, solid initial distribution, product and market validation, and intellectual property. Coupled with recent company moves towards improving their bottom line, OxySure has worked hard to greatly enhance their shareholders’ value.
For more information, investors can see the following resources:
Please read our Full Disclaimer pertaining to this article.